Valuation: Evofem Biosciences, Inc.

Market Cap 1.06M 927K 854K 795K 1.5M 100M 1.53M 10.27M 3.98M 49.29M 3.97M 3.88M 172M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.47M 48.71M 44.83M 41.78M 78.79M 5.27B 80.39M 539M 209M 2.59B 208M 204M 9.01B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day+10.41%
1 week+1.15%
Current month+10.00%
1 month+23.94%
3 months+1.15%
6 months-7.37%
Current year-7.37%
1 week 0.01
Extreme 0.0075
0.01
1 month 0.01
Extreme 0.0064
0.01
Current year 0
Extreme 0.0008
0.01
1 year 0
Extreme 0.0008
0.02
3 years 0
Extreme 0.0008
1.4
5 years 0
Extreme 0.0008
2,062.5
10 years 0
Extreme 0.0008
23,549.99
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
12/01/24Sell

Chief Financial Officer

104 0.0010%
21/12/23Sell

Director

10 0.0001%
13/04/23Other

Chief Financial Officer

13,000 0.0107%
Change 5-day change 1-year change 3-year change Capi.($)
+10.41%+1.15%-11.11%-98.90% 1.06M
-0.64%+6.67%+53.59%+158.28% 1,070B
+0.00%+5.39%+62.89%+55.48% 611B
-0.23%+6.88%+32.14%+85.96% 445B
-3.05%+4.18%+31.11%+23.88% 329B
-1.74%+1.94%+36.90%+22.86% 290B
-1.25%+1.28%+29.98%+38.89% 287B
+2.99%+5.28%-26.30%-41.06% 213B
-0.22%+2.82%+24.37%+60.58% 195B
-0.29%+0.65%+12.75%+64.21% 157B
Average +0.53%+4.03%+24.63%+37.02% 359.62B
Weighted average by Cap. -0.60%+6.67%+39.14%+77.92%

Financials

2024 2025
Net sales 19.36M 17M 15.65M 14.58M 27.5M 1.84B 28.06M 188M 72.92M 904M 72.7M 71.13M 3.14B 20.18M 17.72M 16.31M 15.2M 28.66M 1.92B 29.25M 196M 76.01M 942M 75.78M 74.14M 3.28B
Net income -8.86M -7.78M -7.16M -6.67M -12.58M -842M -12.84M -86.12M -33.37M -413M -33.27M -32.55M -1.44B 391K 343K 316K 294K 555K 37.17M 567K 3.8M 1.47M 18.25M 1.47M 1.44M 63.5M
Net Debt 45.84M 40.25M 37.05M 34.52M 65.1M 4.36B 66.43M 446M 173M 2.14B 172M 168M 7.45B 54.42M 47.78M 43.98M 40.98M 77.29M 5.17B 78.86M 529M 205M 2.54B 204M 200M 8.84B
Logo Evofem Biosciences, Inc.
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
29
Date Price Change Volume
01/07/26 $0.008800 +10.41% 2,247,181
30/06/26 $0.007970 -3.80% 10,231
29/06/26 $0.008285 +1.04% 32,417
26/06/26 $0.008200 -6.02% 278,264
25/06/26 $0.008725 0.00% 76,539

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EVFM Stock